Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Cote D'Azur, Nice, France.
University of Lyon 2, Lyon, France.
Breast. 2020 Feb;49:274-280. doi: 10.1016/j.breast.2020.01.003. Epub 2020 Jan 9.
To address the different partial breast re-irradiation techniques available in the context of second conservative treatment (SCT), as an alternative to salvage mastectomy, for 2nd ipsilateral breast tumor event (IBTE) and summarize their respective oncological and toxicity outcomes.
A literature search was made based on MeSH/PubMed, including papers from 1995 to 2019. Each article was described according to the main irradiation technique, fractionation, oncological results and grade 3 toxicities related to the salvage conservative treatment.
Twenty-two articles were identified, reporting the outcomes of over 1 000 patients. MIB Brachytherapy was the most used re-irradiation technique in case of SCT, with a median 3rdIBTE-FS rate of 88% and summed up grade 3 toxicities of 6%. As for IORT, the average rate of 3rdIBTE-FS was about Finally, external beam partial re-irradiation was recently tested in this indication with encouraging results in terms of tolerance.
When presenting a 2ndIBTE, a SCT can safely be proposed to carefully selected and well-informed patients, as an alternative to salvage mastectomy. MIB appears to be the first intention and most robust choice. IORT, external beam radiotherapy and balloon brachytherapy are interesting alternatives but have only been tested in small series. Further investigations are required and their use should be limited to clinical trial only.
针对 2 次同侧乳房肿瘤事件(IBTE)作为挽救性乳房切除术替代方案的第 2 次保乳治疗(SCT)中可用的不同局部乳房再放疗技术,总结其各自的肿瘤学和毒性结果。
根据 MeSH/PubMed 进行文献检索,包括 1995 年至 2019 年的论文。根据主要放疗技术、分割、肿瘤学结果和与挽救性保乳治疗相关的 3 级毒性,对每篇文章进行描述。
共确定了 22 篇文章,报道了超过 1000 例患者的结果。在 SCT 中,MIB 近距离放疗是最常用的再放疗技术,中位 3 次 IBTE-FS 率为 88%,总 3 级毒性为 6%。对于 IORT,平均 3 次 IBTE-FS 率约为最后,外照射局部再放疗最近在该适应证中进行了测试,在耐受性方面取得了令人鼓舞的结果。
当出现第 2 次 IBTE 时,可以安全地向精心挑选且知情同意的患者提出 SCT,作为挽救性乳房切除术的替代方案。MIB 似乎是首选且最可靠的选择。IORT、外照射放疗和球囊近距离放疗是很有前途的替代方案,但仅在小系列中进行了测试。需要进一步研究,其使用应仅限于临床试验。